Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis

Oncogene

Volumn 34, Issue 12, 2015, Pages 1510-1519

  Miller, A ^a   Brooks, G D ^a   McLeod, L ^a   Ruwanpura, S ^a   Jenkins, B J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; CARCINOGEN; GLYCOPROTEIN GP 130; IL6 PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN; IL6ST PROTEIN, MOUSE; INTERLEUKIN 6; INTERLEUKIN-6, MOUSE; NITROSAMINE;

ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MOUSE; NON SMALL CELL LUNG CANCER; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NITROSAMINES;

EID: 84897967118     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.99     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
2. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc 2008; 5: 811-815.
3. Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer 2012; 77: 2-8.
4. Akopyan G, Bonavida B. Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol 2006; 29: 745-752.
5. West K, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogeninduced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004; 64: 446-451.
6. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111: 81-90.
7. Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene 2011; 30: 1812-1821.
8. Yang Y, Zhang Z, Mukherjee AB, Linnoila RI. Increased susceptibility of mice lacking Clara cell 10-kDa protein to lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a potent carcinogen in cigarette smoke. J Biol Chem 2004; 279: 29336-29340.
9. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in hum an tumors. Oncogene 1999; 18: 813-822.
10. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006; 24: 306-314.
11. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997.
12. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK et al. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2003; 12: 660-664.
13. Vicent S, Lopez-Picazo J, Toledo G, Lozano MD, Torre W, Garcia-Corchón C et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004; 90: 1047-1052.
14. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71: 1095-1098.
15. Gao S, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117: 3846-3856.
16. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011; 103: 1112-1122.
17. Haura EB, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 273-275.
18. Halappanavar S, Russell M, Stampfli MR, Williams A, Yauk CL. Induction of the interleukin 6/signal transducer and activator of transcription pathway in the lungs of mice sub-chronically exposed to mainstream tobacco smoke. BMC Med Genomics 2009; 2: 56.
19. Liu X. STAT3 activation inhibits human bronchial epithelial cell apoptosis in response to cigarette smoke exposure. Biochem Biophys Res Commun 2007; 353: 121-126.
20. Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther 2011; 15: 347-352.
21. Qu P, Roberts J, Li Y, Albrecht M, Cummings OW, Eble JN et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 2009; 63: 341-347.
22. Tebbutt N, Giraud AS, Inglese M, Jenkins BJ, Waring P, Clay FJ et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8: 1089-1097.
23. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005; 11: 845-852.
24. Hollander M, Balogh AR, Liwanag J, Han W, Linnoila RI, Anver MR et al. Strainspecific spontaneous and NNK-mediated tumorigenesis in Ptenmice. Neoplasia 2008; 10: 866-872.
25. Jerome-Marson V, Mazieres J, Groussard O, Garcia O, Berjaud J, Dahan M et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology 2004; 45: 125-134.
26. McClelland MR, Carskadon S, Zhao L, White ES, Beer DG, Orringer MB et al. Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol 2007; 36: 343-350.
27. Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II et al. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Mol Cell Biol 2011; 31: 4270-4285.
28. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705-719.
29. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2() mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104: 687-695.
30. Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001; 34: 59-65.
31. Tominaga M, Sueoka N, Irie K, Iwanaga K, Tokunaga O, Hayashi S et al. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer 2003; 40: 45-53.
32. Ahrendt S, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, Yang SC et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92: 1525-1530.
33. Ruwanpura SM, McLeod L, Miller A, Jones J, Vlahos R, Ramm G et al. Deregulated Stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice. Am J Physiol Lung Cell Mol Physiol 2012; 302: L627-L639.
34. Ramakrishna G, Perella C, Birely L, Diwan BA, Fornwald LW, Anderson LM. Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2002; 179: 21-34.
35. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007; 67: 4933-4949.
36. Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 2012; 72: 3048-3059.
37. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 2004; 279: 40209-40219.
38. Greenberg AK, Hu J, Basu S, Hay J, Reibman J, Yie T-a et al. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle Regulators. Am J Respir Cell Mol Biol 2002; 27: 320-328.
39. Huang RY, Li M, Hsin MK, Underwood MJ, Ma LT, Mok TS et al. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene 2011; 30: 106-116.
40. Takahashi-Tezuka M, Yoshida Y, Fukada T, Ohtani T, Yamanaka Y, Nishida K et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol 1998; 18: 4109-4117.
41. Thiem S, Pierce T, Palmieri M, Putoczki TL, Buchert M, Preaudet A et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest 2013; 123: 767-781.
42. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117: 3846-3856.
43. Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C et al. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene 2012; 32: 151-159.
44. Ihara S, Kida H, Arase H, Tripathi LP, Chen YA, Kimura T et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res 2012; 72: 2990-2999.
45. Hollander M, Zhou X, Maier CR, Patterson AD, Ding X, Dennis PA. A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis 2011; 32: 1279-1284.
46. Razani-Boroujerdi S, Sopori ML. Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility. Am J Respir Cell Mol Biol 2007; 36: 13-19.
47. Ruwanpura SM, McLeod L, Miller A, Jones J, Bozinovski S, Vlahos R et al. Interleukin-6 promotes Pulmonary Emphysema Associated with Apoptosis in Mice. Am J Respir Cell Mol Biol 2011; 45: 720-730.
48. Kennedy CL, Najdovska M, Jones GW, McLeod L, Hughes NR, Allison C et al. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. J Pathol 2011; 225: 255-264.
49. Tye H, Kennedy C, Najdovska M, McLeod L, McCormack W, Hughes N et al. STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation. Cancer Cell 2012; 22: 466-478.